Since its start, AMP has set itself apart by focusing exclusively on CLTI, a condition that is deadlier than most cancers.

The Amputation Prevention Symposium (AMP) is commemorating its 15th anniversary by doing what it does best — addressing chronic limb-threatening ischemia (CLTI), one of the most urgent issues in vascular medicine today.

This complex and devastating disease continues to challenge both patients and healthcare providers, and AMP 2025 is poised to tackle these challenges head-on. AMP 2025 will be held August 13-16 in Chicago and will focus on “AMP Ahead: Where the Field Moves Ahead,” presenting a bold vision for the future of CLTI care.

Since its start, AMP has set itself apart by focusing exclusively on CLTI, a condition that is deadlier than most cancers. Today, AMP remains the leading symposium dedicated to advancing the care of patients facing potential limb loss. We are focused on the road ahead, leading the way toward new innovations, cutting-edge treatment, and more effective patient care.

I am looking forward to presenting sessions at this year’s AMP:

• “How Important is Intra-Luminal Crossing for Vessel Prep,” to be held 5:17-5:25 p.m. Thursday, August 14;
• “Session 11: Multidisciplinary Approach for Optimal Management of the CLI Patient,” to be held from 3-4:15 p.m. Friday, August 15; and
• Two panel discussions, to be held Thursday evening and Friday evening, with my colleagues and the world-class expert faculty at this year’s conference.

Urgency of Our Work

The statistics on CLTI are staggering. Nearly 40% of patients with CLTI face major amputation within the first six months after presentation, and the one-year mortality rate ranges between 20-25%, primarily due to cardiovascular events. As CLTI affects about 10% of those with peripheral artery disease (PAD), we must stay at the forefront of research, treatment strategies, and technologies to improve patient outcomes. 

To address this, at AMP we are dedicated to pushing boundaries, embracing emerging technologies, and continuing to advance the field with urgency and purpose. 

A major component of AMP 2025 is the second annual DVA Day, dedicated to deep vein arterialization (DVA), a groundbreaking approach for patients suffering from CLTI and end-stage plantar disease. By mastering DVA principles, indications, and patient selection criteria, clinicians can expand their treatment arsenal, offering patients a vital alternative to major amputation.

AMP will also showcase advancements in CLTI management through high-impact sessions, including live case demonstrations, hands-on workshops, and expert led discussions. Participants will gain insights into the latest techniques in drug elution, atherectomy, vessel preparation, chronic total occlusion (CTO) strategies, the business of CLTI, as well as crucial topics like complications, imaging, and diagnosis in CLTI. 

These aren’t just theoretical issues; they’re the daily struggles faced by healthcare providers on the front lines of limb preservation. Through dynamic workshops, live cases, and multidisciplinary collaboration, we are building a forum where today’s challenges meet tomorrow’s solutions.

Join us in Chicago

AMP isn’t just a conference — it’s a movement aimed at transforming the way CLTI is treated and managed. AMP will be invaluable for healthcare professionals working in the field of CLTI and PAD. Through interdisciplinary collaboration, innovative technologies, and hands-on learning, AMP has become a platform for positive change. 

Make your plans early for AMP 2025. The lowest registration rates are available through May 2, and the hotel cut-off date for discounted rates is July 11. For more details on rates and registration, visit the AMP website.

Together, we are driving the future of limb preservation, ensuring better outcomes and brighter futures for patients worldwide.

Dr. John Phillips is System Director of OhioHealth Vascular Institute at OhioHealth Riverside Methodist Hospital OhioHealth. He speaks nationally and internationally on peripheral arterial disease and has authored numerous papers in peer-reviewed journals.